ArticleMolecular psychiatry2026
Psilocybin restores social novelty investigation in male SAPAP3 knockout mice and engages prefrontal-hippocampal circuitry.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obsessive-compulsive disorder (OCD) remains difficult to treat, and evidence indicates that social dysfunction, common across obsessive-compulsive and related disorders, is an under-recognized clinical burden. SAPAP3 knockout (KO) mice, a well-established model of compulsive behavior, exhibit social abnormalities, suggesting broader disruptions in circuits relevant to social cognition. Here, we investigated whether psilocybin, a serotonergic psychedelic with emerging therapeutic potential, can restore social behavior in SAPAP3 KO mice and whether behavioral rescue is associated with modulation of neural activity. Male and female SAPAP3 KO mice and wild-type littermates received a 1 mg/kg psilocybin intraperitoneal injection, and social behavior was assessed seven days later using the three-chamber social interaction test. Psilocybin produced a male-specific, enduring restoration of novel-mouse-directed investigation during social recognition/novelty testing. Immunohistochemical quantification of c-Fos revealed that psilocybin increased neural activation in the medial prefrontal cortex and hippocampus regardless of genotype. Only infralimbic c-Fos levels correlated with improved social recognition/novelty behavior in male SAPAP3 KO mice, identifying infralimbic recruitment as a key correlate of therapeutic rescue. Psilocybin did not alter c-Fos in the nucleus accumbens, basolateral amygdala, or dorsal striatum. These findings demonstrate that psilocybin exerts domain-specific, enduring effects on social cognition in an established model of compulsive-like behavior, potentially involving prefrontal plasticity-related mechanisms. Given the lack of pharmacological treatments targeting social dysfunction in OCD and associated neuropsychiatric disorders, these results highlight psilocybin as a promising candidate for improving social-cognitive outcomes in disorders characterized by repetitive behaviors and social impairment.
Identifiers
42754621What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.